DEC 27, 2016 6:52 PM PST

New Experimental Drug To Mend Heart Failure

WRITTEN BY: Kara Marker

Cimaglermin, a new drug under investigation, could be the future of cardiovascular medicine. A new study from scientists at Vanderbilt show the possibility of the drug for the restoration of cardiac function after heart failure, a leading cause of death for Americans.

Source: www.abouthf.org

More often than not, heart failure patients with severe left ventricular systolic dysfunction in particular do not respond well to current methods of treatment, which led researchers to cimaglermin as an alternative.

Led by Vanderbilt’s Daniel L. Lenihan, MD, researchers conducted a study with 40 heart failure patients who had all been receiving optimal medical therapy post-heart failure for at least three months before they entered the trial and began receiving cimaglermin. However, the researchers only examined the effects on safety and efficacy for a single dose of cimaglermin.

Compared to control participants who were just given a placebo, participants who received the single infusion of cimaglermin showed a substantial increase in pumping capacity, measured in terms of left ventricular ejection fraction. While still an experimental drug, cimaglermin was already being shown to boost the natural mechanisms for repairing all aspects of heart: structural, metabolic, and contractile elements.

“Instead of blocking the fundamental mechanisms that lead to cardiac injury, the early results with cimaglermin suggest that it may also be possible to administer therapeutics that allow the failing heart to repair itself using its own repair mechanisms,” explained Douglas L. Mann, MD, FACC, editer-in-chief of JACC: Back to Translational Science. The current study showed that the most common side effects of the drug were nausea and headaches.

“As with all experimental therapeutics, additional studies will be required and subject to regulatory review to determine if the relative risks and benefits of cimaglermin warrant approval,” said Lenihan. Studies will continue with more participants and more doses of the drug.

Lenihan’s study was recently published in the journal JACC: Basic to Translational Science.

Sources: Vanderbilt University, American College of Cardiology

About the Author
I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 08, 2022
Cardiology
Overwork Can Lead to Heart Disease, Strokes, and Death
FEB 08, 2022
Overwork Can Lead to Heart Disease, Strokes, and Death
Overwork kills hundreds of thousands of people every year; working from home probably hasn't helped.
MAR 10, 2022
Cardiology
Blood Pressure Rose Due to the COVID-19 Pandemic
MAR 10, 2022
Blood Pressure Rose Due to the COVID-19 Pandemic
COVID-19 disrupted the lives of millions of people, and two new studies have shown that it also increased blood pressure ...
APR 04, 2022
Plants & Animals
Study Reveals How Much Avocado Can Lower Risk Of Cardiovascular Disease
APR 04, 2022
Study Reveals How Much Avocado Can Lower Risk Of Cardiovascular Disease
It’s well known that avocados pack a health punch. That’s because they’re filled with healthy unsatura ...
MAY 25, 2022
Clinical & Molecular DX
Deadly Heart Arrhythmia Linked to Air Pollution May be Avoidable
MAY 25, 2022
Deadly Heart Arrhythmia Linked to Air Pollution May be Avoidable
Doctors at the Maggiore Hospital in Bologna, Italy noticed that on days with high levels of air pollution, clusters of p ...
JUN 04, 2022
Drug Discovery & Development
3g of Omega-3 Fatty Acids Daily May Lower Blood Pressure
JUN 04, 2022
3g of Omega-3 Fatty Acids Daily May Lower Blood Pressure
Around 3g of omega-3 fatty acids taken on a daily basis may be the optimal dose for lowering blood pressure. The corresp ...
JUN 25, 2022
Neuroscience
'Feeling Younger' Boosts Rehabilitation Outcomes in Older Patients
JUN 25, 2022
'Feeling Younger' Boosts Rehabilitation Outcomes in Older Patients
How old a person feels is more predictive of their rehabilitation outcome than their chronological age and underlying he ...
Loading Comments...